| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ramona Pais, Tamara Zietek, Hans Hauner, Hannelore Daniel, Thomas Skur. RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. American journal of physiology. Gastrointestinal and liver physiology. vol 307. issue 3. 2014-09-29. PMID:24875103. |
rantes exposure to mouse intestinal tissues lowers transport function of the intestinal glucose transporter sglt1, and administration in mice reduces plasma glp-1 and glp-2 levels after an oral glucose load and thereby impairs insulin secretion. |
2014-09-29 |
2023-08-13 |
mouse |
| Janine J Geerling, Mariëtte R Boon, Sander Kooijman, Edwin T Parlevliet, Louis M Havekes, Johannes A Romijn, Illiana M Meurs, Patrick C N Rense. Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies. Journal of lipid research. vol 55. issue 2. 2014-09-28. PMID:24285857. |
various neuronal populations, such as neuropeptide y (npy)-expressing neurons and melanocortin-expressing neurons, as well as peripherally produced hormones (i.e., glp-1, leptin, and insulin), modulate sympathetic outflow from the hypothalamus toward target organs and thereby influence peripheral tg metabolism. |
2014-09-28 |
2023-08-12 |
Not clear |
| Baicheng Ma, Peipei Tu, Xingyu Zhao, Yaofang Zhang, Yu Wang, Chao Ma, Yanli Ji, Xiaodan Li, Syed A Abbas, Minggang L. Expression and purification of optimized rolGLP-1, a novel GLP-1 analog, in Escherichia coli BL21(DE3) and its good glucoregulatory effect on type 2 diabetic mice. Current pharmaceutical biotechnology. vol 14. issue 11. 2014-09-25. PMID:24372241. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that decreases postprandial glycemic excursions by enhancing insulin secretion but with short half-life due to rapid inactivation by enzymatic n-terminal truncation. |
2014-09-25 |
2023-08-12 |
mouse |
| Takashi Iwai, Toshihiro Sawabe, Kahori Tanimitsu, Manabu Suzuki, Sachie Sasaki-Hamada, Jun-Ichiro Ok. Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. Journal of neuroscience research. vol 92. issue 4. 2014-09-23. PMID:24464856. |
glucagon-like peptide-1 (glp-1) is derived from the processing of proglucagon in intestinal l-cells and releases insulin from pancreatic β-cells as an incretin. |
2014-09-23 |
2023-08-12 |
rat |
| Jifeng Zhang, Changyong Xue, Tianqing Zhu, Anuradha Vivekanandan, Subramaniam Pennathur, Zhongmin Alex Ma, Y Eugene Che. A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. PloS one. vol 8. issue 12. 2014-09-16. PMID:24386218. |
a tripeptide diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and glp-1. |
2014-09-16 |
2023-08-12 |
mouse |
| Jifeng Zhang, Changyong Xue, Tianqing Zhu, Anuradha Vivekanandan, Subramaniam Pennathur, Zhongmin Alex Ma, Y Eugene Che. A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. PloS one. vol 8. issue 12. 2014-09-16. PMID:24386218. |
effective therapies, such as insulin and glucagon-like peptide-1 (glp-1), require injections, which are costly and result in less patient compliance. |
2014-09-16 |
2023-08-12 |
mouse |
| Jifeng Zhang, Changyong Xue, Tianqing Zhu, Anuradha Vivekanandan, Subramaniam Pennathur, Zhongmin Alex Ma, Y Eugene Che. A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. PloS one. vol 8. issue 12. 2014-09-16. PMID:24386218. |
furthermore, we found that plasma glp-1 and insulin levels in diabetic models were significantly increased with diapin treatment compared to that in the controls. |
2014-09-16 |
2023-08-12 |
mouse |
| Jifeng Zhang, Changyong Xue, Tianqing Zhu, Anuradha Vivekanandan, Subramaniam Pennathur, Zhongmin Alex Ma, Y Eugene Che. A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. PloS one. vol 8. issue 12. 2014-09-16. PMID:24386218. |
in summary, our findings establish that a peptide with minimum of three amino acids can improve glucose homeostasis and diapin shows promise as a novel pharmaceutical agent to treat patients with t2d through its dual effects on glp-1 and insulin secretion. |
2014-09-16 |
2023-08-12 |
mouse |
| Irl B Hirsch, Doron Schneider, Aaron King, William H Polonsky, Timothy S Reid, Jay Shubrook, Carol A Verderese, Jeffrey Wallace, Matthew C Riddl. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus. Postgraduate medicine. vol 126. issue 3. 2014-09-08. PMID:24918799. |
a short-acting glp-1 analog or prandial insulin to supplement basal insulin?--moving toward personalized management of type 2 diabetes mellitus. |
2014-09-08 |
2023-08-13 |
Not clear |
| Mary Ann Honors, Kimberly P Kinzi. Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Hormones & cancer. vol 5. issue 1. 2014-09-05. PMID:24101584. |
the present experiment was designed to examine the ability of exendin-4, a glp-1 agonist and insulin sensitizing agent, to prevent the development of cachexia symptoms in male sprague dawley rats bearing the yoshida sarcoma. |
2014-09-05 |
2023-08-12 |
human |
| Kiyoshi Ebihara, Makoto Tachibe, Natsumi Kaneko, Taro Kishid. Hydroxypropylation of high-amylose maize starch changes digestion and fermentation-dependent parameters in rats. Journal of nutritional science. vol 2. 2014-09-05. PMID:25191565. |
plasma glucagon-like peptide-1 (glp-1), glucose and insulin concentrations were not affected by diet. |
2014-09-05 |
2023-08-13 |
rat |
| Kiyoshi Ebihara, Makoto Tachibe, Natsumi Kaneko, Taro Kishid. Hydroxypropylation of high-amylose maize starch changes digestion and fermentation-dependent parameters in rats. Journal of nutritional science. vol 2. 2014-09-05. PMID:25191565. |
these results show that the small intestinal digestibility and fermentation-dependent parameters such as caecal scfa and h2 productions and caecal bacterial profile of hams were affected by hydroxypropylation, but parameters of glucose metabolism such as glp-1 and insulin, those of lipid metabolism such as plasma tag and cholesterol and the amount of caecal iga were not. |
2014-09-05 |
2023-08-13 |
rat |
| Bilal Omar, Bo Ahré. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. vol 63. issue 7. 2014-09-03. PMID:24962916. |
this in turn increases circulating intact glp-1, which results in stimulated insulin secretion and inhibited glucagon secretion, in turn increasing glucose utilization and diminishing hepatic glucose production, which, through reduction in postprandial and fasting glucose, reduces hba1c. |
2014-09-03 |
2023-08-13 |
Not clear |
| Bilal Omar, Bo Ahré. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes. vol 63. issue 7. 2014-09-03. PMID:24962916. |
these nonclassical mechanisms include 1) inhibition of gut dpp-4 activity, which prevents inactivation of newly released glp-1, which in turn augments glp-1-induced activations of autonomic nerves and results in high portal glp-1 levels, resulting in inhibited glucose production through portal glp-1 receptors; 2) inhibition of islet dpp-4 activity, which prevents inactivation of locally produced intact glp-1 in the islets, thereby augmenting insulin secretion and inhibiting glucagon secretion and possibly preventing islet inflammation; and 3) prevention of the inactivation of other bioactive peptides apart from glp-1, such as glucose-dependent insulinotropic polypeptide, stromal-derived factor-1α, and pituitary adenylate cyclase-activating polypeptide, which may improve islet function. |
2014-09-03 |
2023-08-13 |
Not clear |
| Denis Raccah, Jay Lin, Edward Wang, Maeva Germé, Riccardo Perfetti, Riccardo C Bonadonna, Pedro de Pablos-Velasco, Ronan Roussel, Julio Rosenstoc. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. Journal of diabetes and its complications. vol 28. issue 1. 2014-08-27. PMID:24246441. |
to compare the efficacy and safety of lixisenatide (lixi), a once-daily prandial glucagon-like peptide-1 (glp-1) receptor agonist, as add-on to basal insulin (basal+lixi) versus once-daily rapid-acting insulin (basal+rai) in patients with type 2 diabetes mellitus (t2dm). |
2014-08-27 |
2023-08-12 |
Not clear |
| Bénédicte de Kalbermatten, Jaafar Jaafar, François R Jornayvaz, Jacques Philipp. [Combined treatment of insulin and GLP-1 analogs: what do we expect?]. Revue medicale suisse. vol 10. issue 433. 2014-08-25. PMID:25004768. |
[combined treatment of insulin and glp-1 analogs: what do we expect?]. |
2014-08-25 |
2023-08-13 |
Not clear |
| Bénédicte de Kalbermatten, Jaafar Jaafar, François R Jornayvaz, Jacques Philipp. [Combined treatment of insulin and GLP-1 analogs: what do we expect?]. Revue medicale suisse. vol 10. issue 433. 2014-08-25. PMID:25004768. |
glp-1 analogs are effective therapeutic alternatives due to their actions on glucagon and insulin secretion, on satiety and gastric emptying. |
2014-08-25 |
2023-08-13 |
Not clear |
| Bénédicte de Kalbermatten, Jaafar Jaafar, François R Jornayvaz, Jacques Philipp. [Combined treatment of insulin and GLP-1 analogs: what do we expect?]. Revue medicale suisse. vol 10. issue 433. 2014-08-25. PMID:25004768. |
for patients inadequately controlled with conventional antidiabetics, glp-1 analogs, introduced as an alternative or in combination with insulin, can prevent or reduce the side effects associated with insulin. |
2014-08-25 |
2023-08-13 |
Not clear |
| Marwa R Al-Badri, Sami T Aza. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Therapeutic advances in endocrinology and metabolism. vol 5. issue 2. 2014-08-25. PMID:25152810. |
glp-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. |
2014-08-25 |
2023-08-13 |
Not clear |
| Marwa R Al-Badri, Sami T Aza. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Therapeutic advances in endocrinology and metabolism. vol 5. issue 2. 2014-08-25. PMID:25152810. |
we have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of glp-1 in patients with diabetes or who have insulin resistance and psoriasis. |
2014-08-25 |
2023-08-13 |
Not clear |